Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

Company Overview

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: $2.32 to $3.18
• 50-Day Range: $2.15 to $6.78
• 52-Week Range: $2.07 to $32.85
• Volume: 85,373 shs
• Average Volume: 15,634 shs
• Market Capitalization: $4.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Alaunos Therapeutics Stock Analysis - MarketRank™

Alaunos Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 997th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Alaunos Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Alaunos Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.12% of the float of Alaunos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alaunos Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Alaunos Therapeutics has recently increased by 3.48%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alaunos Therapeutics does not currently pay a dividend.

Dividend Growth

Alaunos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.12% of the float of Alaunos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alaunos Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Alaunos Therapeutics has recently increased by 3.48%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Alaunos Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alaunos Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.11% of the stock of Alaunos Therapeutics is held by insiders.

Percentage Held by Institutions

Only 27.72% of the stock of Alaunos Therapeutics is held by institutions.

TCRT Stock Analysis - Frequently Asked Questions

How have TCRT shares performed this year?

Alaunos Therapeutics' stock was trading at $10.6050 on January 1st, 2024. Since then, TCRT stock has decreased by 71.9% and is now trading at $2.98.
View the best growth stocks for 2024 here.

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) issued its earnings results on Wednesday, August, 14th. The company reported ($0.71) earnings per share (EPS) for the quarter.

When did Alaunos Therapeutics' stock split?

Alaunos Therapeutics's stock reverse split on Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/14/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCRT
• CUSIP: N/A
• CIK: 1107421
• Web: www.alaunos.com
• Phone: (346) 355-4099
• Fax: 617-241-2855
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,140,000.00
• Net Margins: N/A
• Pretax Margin: -318,833.31%
• Return on Equity: -265.92%
• Return on Assets: -199.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.16
• Quick Ratio: 5.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.93 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 1,600,000
• Free Float: 15,195,000
• Market Cap: $4.99 million
• Optionable: Optionable
• Beta: -0.56